Endocrine Cancer Clinical Trials
Clinical trials are studies that are important for discovering new therapies and treatments for endocrine cancer. They also seek new ways to detect, diagnose and reduce the chance of developing cancer. The ultimate goal of clinical trials is to improve the lives of our patients. Trials involve collaboration across multiple departments, with researchers involved in design, testing and analysis of these studies.
Orlando Health Cancer Institute Research and Clinical Trials Program focuses on trials designed to assess a wide range of cancer-fighting options. We strive to improve our standards of care and patient outcomes through medications, therapies, genetics, diet and better screening.
Trials also offer our patients an avenue for gaining early access to promising research that may be used to prevent, diagnose and treat endocrine cancer.
Clinical Trials match your criteria
-
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CHS-006, as Monotherapy and in Combination with Toripalimab, in Participants with Advanced Solid Tumors
-
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
-
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART)
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy
-
A Phase 1/2, study of infusion IOV-4001 in patients with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer
A Phase 1/2, open-label study of PD-1 knockout tumor-infiltrating lymphocytes (IOV-4001) in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer
-
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors
-
Determination and Validation of Lung EpiCheck; a Multianalyte Assay for Lung Cancer Prediction
Lung-RND-003: Determination and Validation of Lung EpiCheck; a Multianalyte Assay for Lung Cancer Prediction A Case-Control Study
-
Phase 2 study of Autologous TIL's for patients with solid tumors
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More